{"url_path":"/sec/curx/8-k/2026-05-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022898-index.html","accession_number":"0001493152-26-022898","cik":"0002025942","ticker":"CURX","issuer_name":"Curanex Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/2025942/0001493152-26-022898-index.html","primary_entity_key":"0002025942","primary_entity_name":"Curanex Pharmaceuticals Inc"},"word_count":114,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01. Regulation FD Disclosure.**\n\n** **\n\nCuranex\nPharmaceuticals Inc (the “Company”) today issued a press release with the business update of its developments during first\nquarter of 2026, highlighting its continued progress with Phyto-N, the Company’s lead drug candidate.\n\n \n\nA\ncopy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe\ninformation contained in this Item 7.01, as well as Exhibit 99.1 referenced herein, shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under\nthe Securities Act of 1933, as amended."}